ZP10000
/ Zealand Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 10, 2014
Encycle Therapeutics developing lead molecule to tackle inflammatory bowel disease
(Canada Newswire)
- "Encycle Therapeutics...in partnership with MaRS Innovation, is developing its lead orally-bioavailable macrocycle drug to target integrin a4b7, which is involved in the inflammatory process in a number of diseases, most notably for inflammatory bowel disease."
Licensing / partnership • New molecule • Immunology • Inflammatory Bowel Disease
1 to 1
Of
1
Go to page
1